Consistently, BRCC3 mutations were found in 5 patients in a recent study of 331 t(8;21)(q22;q22.1) AML cases [38], but in only one patient with MDS-related cytogenetic abnormalities in the TCGA de novo AML cohort [29]. The gene discussed is BRCC3; the disease is myelodysplastic syndrome.